Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors

@article{Tranchand1998PhaseIC,
  title={Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors},
  author={Brigitte Tranchand and Gilles Catimel and C. W. Lucas and Marlis Sarkany and G{\'e}rard Bastian and Eric Ev{\`e}ne and J. -P. Guastalla and Sylvie N{\'e}grier and Paul Rebattu and Arlette Dumortier and Maurice Foy and François Grossin and B{\'e}atrice Mazier and Marios E Froudarakis and Nicolas Barbet and Michel Clavel and Claude Joseph Ardiet},
  journal={Cancer Chemotherapy and Pharmacology},
  year={1998},
  volume={41},
  pages={281-291}
}
Purpose: The objectives of this phase I study were to evaluate the toxic effects and the maximum tolerated dose (MTD) of S9788, a new modifier of multidrug resistance (MDR), when given alone and in combination with doxorubicin to patients with advanced solid tumors; to achieve a potentially active plasma concentration of S9788; and to study the pharmacokinetics of both drugs. Methods: A total of 26 patients (median age 58 years) entered the study. S9788 was given alone as a 30-min infusion at… CONTINUE READING
7 Citations
44 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Phase I clinical and pharmacokinetic trials of S9788 alone and in combination with Adriamycin (ADM)

  • A Awada, O Pagani, M Piccard
  • Proc Am Assoc Cancer Res
  • 1993
Highly Influential
3 Excerpts

Lack of interference of S9788 with the pharmacokinetics (PK) of Adriamycin (ADM)

  • D De Valeriola, C Brassinne, C Lucas
  • Proc Am Assoc Cancer Res
  • 1995
1 Excerpt

Phase IB study of S9788, a novel multidrug resistance (MDR) revertant in combination with Adriamycin (ADM) in patients with colorectal (CRC) or renal cell (RCC) cancer

  • E Tueni, F Majois, G Blijham
  • Proc Am Soc Clin Oncol
  • 1995
2 Excerpts

Phase I and pharmacokinetic study of SDZ PSC 833 per os in combination with doxorubicin in patients with solid tumors

  • G Giaccone, SC Linn, G Catimel
  • Proc Am Soc Clin Oncol
  • 1994
2 Excerpts

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance

  • NL Barlett, BL Lum, GA Fisher
  • J Clin Oncol
  • 1994
2 Excerpts

Similar Papers

Loading similar papers…